Deutsche Bank set a CHF 85 price target on Novartis (VTX:NOVN) in a research note released on Tuesday, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.
Other equities analysts have also recently issued research reports about the stock. Jefferies Financial Group set a CHF 105 price target on shares of Novartis and gave the stock a buy rating in a research note on Wednesday, March 27th. JPMorgan Chase & Co. set a CHF 85 target price on shares of Novartis and gave the company a sell rating in a research note on Wednesday, April 3rd. Credit Suisse Group set a CHF 84 target price on shares of Novartis and gave the company a neutral rating in a research note on Thursday, April 25th. HSBC set a CHF 83 target price on shares of Novartis and gave the company a neutral rating in a research note on Thursday, April 25th. Finally, UBS Group set a CHF 82 target price on shares of Novartis and gave the company a neutral rating in a research note on Wednesday, April 24th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the company’s stock. Novartis has a consensus rating of Hold and a consensus price target of CHF 88.29.
Novartis has a one year low of CHF 72.45 and a one year high of CHF 88.30.
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.
Featured Article: What is intrinsic value?
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.